EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, ...

Immuno-oncology (IO) has transformed cancer care ... led to the discovery of novel multi-specific antibodies that target TCR variable beta (Vβ)-chain variants—powerfully activating the right ...

Which is best suited for immuno-oncology? Cancer research and drug ... Checkpoint inhibitors, CAR-T cells, modified TCR T cells, and vaccines in various forms are now the frontier of oncology ...

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator ...

5 (4) A CAR controlled remotely via drugs and other small molecules puts the brakes on T cell activation and prevents exhaustion. 6,7 (5) The T cell receptor (TCR) is a protein complex that recognizes ...

Medigene AG, an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced that the company has been issued a ...

The deal – which included an upfront payment of around $50 million and focused on the development of a pair of autologous and/or allogeneic T-cell receptor (TCR) based therapies – will come to ...

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates ...